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The American Heart Association (AHA) and the American College of Cardiology (ACC) have issued a new joint guideline for the treatment of adults with acquired valvular heart disease, which includes substantial changes of the previous 2008 guideline.
Several important changes and additions are listed:
1. Stages of heart valve disease. For each of the cardiac valves, the guideline describes stages of disease, similar to the classification of heart failure stages based on valve anatomy, valve hemodynamics, hemodynamic consequences, and symptoms: A, at risk; B, progressive; C, asymptomatic severe; and D, symptomatic severe. 2. Cardiac magnetic resonance imaging. The new guideline gives cardiac magnetic resonance imaging a Class I recommendation for the assessment of patients with chronic severe aortic and mitral regurgitation (MR). 3. Exercise testing. Increased emphasis (Class IIa) is placed on the use of exercise testing in the evaluation of asymptomatic patients with severe heart valve disease (particularly aortic stenosis (AS) and primary MR). 11. Low-molecular-weight heparin (LMWH) "bridging" of patients with mechanical heart valve prostheses. LMWH "bridging" is now considered appropriate (Class I) among patients with a mechanical valve at high risk of thrombosis when warfarin needs to be interrupted (previously Class IIb).
Clinical implications and perspective
The new AHA/ACC guideline is a very detailed and comprehensive document, covering many new aspects of acquired adult valvular heart disease. It offers recommendations for the management of native valve disease, prosthetic valves, infective endocarditis, and pregnancy of patients with valvular heart disease. Questions related to cardiac and noncardiac surgery are also covered. The guideline recommends a new staging algorithm and a risk-scoring system. Several additions have been made in answer to new treatment options such as minimally invasive surgical and transcatheter valve interventions.
The new guideline also reflects a shift toward intervening earlier in the course of the disease and provides a new system for classifying patient risk prior to a procedure. Like the European guideline published in 2012, the AHA/ ACC document emphasizes the role of multidisciplinary teams and defines the important role of Heart Valve Teams and Heart Valve Centers of Excellence.
